Dow Jones
39.112,16 -299,05 (-0,76%) Nasdaq
17.717,65 +220,84 (+1,26%) Nikkei 225
39.713,79 +540,64 (+1,38%) EUR/USD
1,0709 -0,0007 (-0,06%) Bitcoin EUR
57.494,11 +540,38 (+0,95%) CMC Crypto 200
1.278,66 -5,12 (-0,40%)
Caribou Biosciences, Inc. (CRBU)
Dopo ore:
| Chiusura precedente | 1,8700 |
| Aperto | 1,8650 |
| Denaro | 1,7500 x 500 |
| Domanda | 1,7800 x 1000 |
| Min-Max giorno | 1,7300 - 1,8650 |
| Intervallo di 52 settimane | 1,6000 - 8,5900 |
| Volume | |
| Media Volume | 2.363.413 |
| Capitalizzazione | 158,959M |
| Beta (mensile su 5 anni) | 2,43 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,3800 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 17,88 |
GlobeNewswireCaribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
Reigin Zawadzki, chief people officer, Caribou Biosciences Caribou biosciences appoints Reigin Zawadzki as chief people officer. BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Reigin Zawadzki to the newly created position of chief people officer. Ms. Zawadzki brings over 20 years of experience leading human resources in the biotechnology ind
GlobeNewswireCaribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: Citi 18th Annual BioPharma Conference, Boston, MASeptember 6, 2023Wells Fargo Healthcare Conference, Boston, MASeptember 7, 2023, 8:00 am EDTMorgan Stanley 21st Annual Global Healthcare Conference, New York, NYSeptember 11, 2023Jefferies Cell & Gene
- GlobeNewswire
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1 trial enrollment continues in r/r MM -- -- CB-012 IND application submission for r/r AML planned for H2 2023 -- -- Received $25.0 million equity investment from Pfizer -- -- Closed upsized public offering including full exercise of underwriters’ option to purchase additional shares, delivering $134.6 mi
